

# HEART FAILURE GUIDELINES FOR U M



Save the date

**19<sup>th</sup> & 20<sup>th</sup>**  
**October**  
**2020**

8<sup>th</sup> edition

**Better understand the heart  
failure guidelines process and its  
implications**

**Location**

**The hotel Arundel Preserve**

7795 Arundel Mills Boulevard - Hanover, MD 21076 - USA

# Attend a TMA Guidelines Forum

## Why a Guidelines Forum on Heart Failure?

The quality of research and development efforts made by manufacturers of pharmacological agents, biomarkers, and medical devices has obviously had a major impact on the position of these products in clinical guidelines on the management of heart failure. Conversely, the success and failure stories that inevitably accompany the release of new guidelines may be a source of inspiration for further research and development. And, ultimately, guidelines really shape clinical practice if doctors and their patients adopt them.

A better understanding of the processes involved in guidelines development will help companies that develop drugs, biomarkers, and devices to adapt and improve their research and development programmes for the future.

This could also translate into earlier and more efficient development of diagnostic and therapeutic tools for patients.

How do guideliners deal with the available evidence and what are their expectations in this respect? What criteria must a product or an intervention meet to be recommended by heart failure guidelines? What are the most frequent reasons for failure? Why may guidelines of geographically distinct origins but dealing with the same evidence occasionally reach different

### Format

A series of short presentations and discussions with a focus on practical examples, case studies and interactivity between Faculty members.

### Who should attend?

Attendees include industry representatives with interest in clinical trials, product development, market access, guidelines development and implementation, patients' advocacy specialists, clinical research organizations and payers.

### About TMA

The Translational Medicine Academy (TMA) is an international academic Foundation with focused activities in Mission Critical Areas of high public health importance having significant professional and patient therapeutic and educational gaps.

### Why a Heart Failure Guidelines Forum?

The objective is to better understand the existing Heart Failure guidelines development process and its implications in clinical practice. It is not to develop new guidelines, but to gather a multidisciplinary panel of leading international experts to discuss the latest evidence, ongoing research and controversial issues that have implications for the development of clinical practice guidelines.

### Educational objectives

At the end of the meeting, all participants will have a better understanding of the unmet needs and knowledge gaps that need to be addressed by future research and development efforts, and of the most appropriate ways of progressing to conciliate and take advantage of clinical, societal, evidence-based medicine and regulatory requirements.

conclusions? What should be done to avoid that guidelines being lost in translation? How can we adapt the guidelines for low and middle income countries?

Speakers and discussants who will address these topics have been selected from among the top-level North American and international experts in cardiology who participate in the regular update of guidelines. The faculty also comprises clinicians with a strong interest in translational and patient-centered medicine.

The Heart Failure Guidelines Close Forum will be strictly academic – meaning that attendees will not participate during the main sessions and discussions. However, they will be able to transmit written questions to the faculty.

Without any doubt, the Heart Failure Guidelines is a rare opportunity.

This event is registered with MedTech Europe and declared (provisionally) compliant: <https://www.ethicalmedtech.eu/>

# Preliminary information

## Chairs



**Prof. William Abraham**

MD, FACP, FACC, FAHA,  
FESC, FRCPE

Professor of Medicine,  
Physiology, and Cell Biology  
College of Medicine,  
Distinguished Professor,  
Division of Cardiovascular  
Medicine, the Ohio State  
University, USA



**Prof. Stefan Anker**

MD, PhD, FESC

Professor of cardiology  
and Cachexia Research,  
Department of Cardiology  
Charité Campus Virchow-  
Klinikum Berlin, Germany



**Prof. Javed Butler**

MD, MPH, MBA

Professor and Chairman  
of the Department of  
Medicine at the University  
of Mississippi in Jackson,  
Mississippi, USA, Patrick  
H. Lehan Chair in  
cardiovascular Research,  
Professor of physiology



**Prof. Andrew Coats**

DM, DSc, MBA, AO

President-elect, Heart  
Failure Association of the  
ESC, Academic Vice-  
President Monash-Warwick  
Alliance, Monash University,  
Melbourne, Australia,  
University of Warwick,  
Coventry, UK

## Contact us

### Organization

Charles Schoen - Operations Director

Tel.: +33 (0) 6 08 18 77 08

Email: [charles.schoen@tmacademy.org](mailto:charles.schoen@tmacademy.org)

### Registration

Yann Colardelle

Tel.: + 33 (0) 6 71 91 99 77

E-mail: [yanncol@mededgs.com](mailto:yanncol@mededgs.com)

[www.tmacademy.org](http://www.tmacademy.org)

An opportunity to meet  
**a panel of international experts**  
in **Heart Failure**

**HEART FAILURE**  
**GUIDELINES**  
**FOR URM**

